AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus
← catalyst calendarNCT06265220 · readout ≤ 377 d
Sponsored by Artiva Biotherapeutics, Inc. (industry) · ARTV — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
51estimated
Sites
9
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-04-03 | actual | When the study began enrolling |
| Primary completion | Aug 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2024-02-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Lupus Nephritis - WHO Class III
- Lupus Nephritis - WHO Class IV
- Refractory Systemic Lupus Erythematosus
- SLE
Interventions
- Drug: AB-101
- Drug: Cyclophosphamide
- Drug: Fludarabine
- Drug: Rituximab
- Drug: Obinutuzumab
Primary outcomes
what the primary-completion date above is the date OFIncidence of Treatment-Emergent Adverse Events and Serious Adverse Events
measured From the time of consent through 104 weeks after initiation of study treatment
AB-101 Clinical Activity
measured From the time of first dose through 104 weeks after initiation of study treatment
Permalink · ARTV's whole pipeline · Catalyst calendar · Every registered study · What changed